SAN FRANCISCO, Calif. and SUZHOU, China, May 25, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced that Adagene’s Co-founder, Chief Executive Officer and Chairman, Peter Luo, Ph.D., will provide a corporate update and participate in one-on-one investor meetings at the Jefferies Virtual Healthcare Conference to be held June 1-4, 2021 and the Goldman Sachs 42nd Annual Global Healthcare Conference to be held June 8-11, 2021.
Details on the presentations can be found below.
Jefferies Virtual Healthcare Conference
Date: Friday, June 4, 2021
Presentation Time: 10:00 AM ET
Webcast: Click Here
Goldman Sachs 42nd Annual Global Healthcare Conference
Date: Thursday, June 10, 2021
Presentation Time: 5:30 PM ET
Webcast: Click Here
About Adagene
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Powered by its proprietary DPL platform, composed of NEObody, SAFEbody, and POWERbody technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science.
For more information, please visit: https://investor.adagene.com.
Investors Contact:
Raymond Tam
Adagene
86-512-8777-3626
ir@adagene.com
Bruce Mackle
LifeSci Advisors
646-889-1200
bmackle@lifesciadvisors.com
Media Contact:
Annie Starr
6 Degrees
973-768-2170
astarr@6degreespr.com